<DOC>
	<DOCNO>NCT00663091</DOCNO>
	<brief_summary>To test safety efficacy Bacteriophage Venous Leg Ulcers .</brief_summary>
	<brief_title>A Prospective , Randomized , Double-Blind Controlled Study WPP-201 Safety Efficacy Treatment Venous Leg Ulcers</brief_title>
	<detailed_description>This prospective , randomize , control double blind study patient full thickness venous leg ulcer great 30 day duration evaluate safety WPP-201 healing wound .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Leg Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<criteria>1 . Subject must evidence hemosiderosis , stasis dermatitis , dermato liposclerosis ; AND edema low extremity wound present . 2 . Subject must least 18 year age . 3 . Subject must minimum life expectancy least 1 year determine Investigator . 4 . The postdebridement ulcer Day 0 must free necrotic tissue undermine . 5 . The study ulcer must 1 cm2 60 cm2 size . 6 . The study ulcer must present great 30 day study Day 7 . 7 . The study ulcer separate least 4 cm ulcer Study Day 7 Study Day 0 margin intact skin sufficient anchoring require study dressing . 8 . The subject ' Glycosylated hemoglobin ( HbA1C ) must equal less 10.0 % subject diagnose diabetes study Day 0 . 9 . The subject , legal guardian authorize representative must understand , sign dated IRB approve informed consent form . 10 . The subject must available evaluation weekly basis twelve ( 12 ) week study . Visits Week 13 Week 14 require initial wound healing , achieve study Week 11 12 . The Investigator evaluate group Week 16 Month 6 . Subjects must available evaluation Week 16 Month 6 . 11 . Subjects ' TCpO2 must equal great 20 mm mercury ABI great 0.7 . 1 . Subject whose ulcer heal 30 % great evaluation Study day 7 postdebridement Study Day 0 determine wound tracing use VisitrakTM . 2 . A history alcohol substance abuse , within previous year , could , judgment Investigator , would interfere study compliance protocol requirement . 3 . Participation clinical trial evaluate investigational pharmaceutical biologics within 3 month device within 30 day admission study . 4 . Subject history receiving follow within last 30 day : systemic corticosteroid exceed total daily dose 20mg , immunosuppressive agent , radiation therapy chemotherapy . Anticipated use study period also exclude subject entry study . Topical inhale corticosteroid prohibit . 5 . Subject exclude : Serum sodium le 130 great 147 Potassium great 5.4 less 3.3 Glucose less 55 Blood urea nitrogen great 31 Creatinine great 2.1 Calcium less 7 CPK great 3 time upper limit normal Albumin le 2.5 Total protein le 5 Alkaline phosphatase great 3 time upper limit normal ALT/AST great 5 time upper limit normal Hemoglobin le 8 White blood count great 20,000 1,000 6 . Subject pregnant , lactate positive serum hCG determine laboratory test exclude study . 7 . Subject demonstrate allergy component WPP201 ( phage saline ) . 8 . Subject previously receive application bacteriophage .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>WPP-201</keyword>
</DOC>